PaulHWakefieldMD

Family Medicine • Knoxville, TN

Physician

Join to view full profile

Dr. Wakefield is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wakefield's full profile

Already have an account?

Office
1208 Merchant Dr
Knoxville, TN 37912
Phone+1 865-688-2522

Education & Training

University of Tennessee Medical Center at KnoxvilleResidency, Family Medicine, 1987 - 1990
University of Tennessee Health Science Center College of MedicineClass of 1987

Certifications & Licensure

TN State Medical License 1988 - 2025

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Diabetes Recognition Program National Committee for Quality Assurance, 2012-2015
Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2013
Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2013
Heart/Stroke Recognition Program National Committee for Quality Assurance, 2011-2014
Diabetes, Cardiac Care Recognition Health Care Incentives Improvement Institute
Join now to see all

Clinical Trials

Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis Start of enrollment: 2013 Dec 01
Completed
Phase 3
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus Start of enrollment: 2010 Jun 18
Completed
Phase 3
The Plecanatide Chronic Idiopathic Constipation (CIC) Study Start of enrollment: 2011 Oct 01
Completed
Phase 2, Phase 3
Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC) Start of enrollment: 2013 Aug 01
Completed
Phase 3
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes Start of enrollment: 2014 May 01
Completed
Phase 3
Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM Start of enrollment: 2015 Sep 01
Completed
Phase 2
Anthrax AV7909 Boost Evaluation Study Start of enrollment: 2023 Dec 05
Recruiting
Phase 2
Roles: Contact
Join now to see all